---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-025827"
form_type: "8-K"
ticker: "BCDA"
cik: "0000925741"
company_name: "BioCardia, Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T16:01:39.230270+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BioCardia Q2 net loss $2M, cash ~$1.1M after ATM; runway into Oct 2025

## Summary
- Net loss of $2.0M for Q2 2025 vs $1.6M in Q2 2024; R&D expenses up to $1.4M.
- Cash balance $980k at June 30; raised $769k via ATM at avg $2.59/share; runway into Oct 2025.
- R&D expenses increased due to closeout of CardiAMP HF trial and start of CardiAMP HF II enrollment.
- Phase 3 CardiAMP HF data submitted to Japan PMDA; FDA meetings on approvability expected Q4 2025.
- Helix transendocardial delivery system DeNovo 510(k) submission planned Q3 2025.

## SEC filing metadata
- accession: 0001437749-25-025827
- form_type: 8-K
- ticker: BCDA
- cik: 0000925741
- company_name: BioCardia, Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/925741/000143774925025827/0001437749-25-025827-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/925741/000143774925025827/bcda20250811_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-025827
- JSON: https://secwatch.observer/filing/0001437749-25-025827.json
- Plain text: https://secwatch.observer/filing/0001437749-25-025827.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.